THE DEAL, AT A GLANCE
From the announcementVividion Therapeutics
01Who is involvedBacked by Bain Capital Life SciencesFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedVividion Therapeutics raised $110M Series CFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersVividion Therapeutics is positioned around chemoproteomics AI for small molecule drug discovery, targeting disease targets described as undruggable and using Series C…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Vividion Therapeutics · Financing Record
Explore source-linked visual explanations for Vividion Therapeutics. Unsupported claims are withheld while source review continues.
Record 571 · Recorded date: Needs review
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →